Silexion Therapeutics Ltd.
Silexion Therapeutics Ltd. (SLXNW) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · SLXNW · as of Sep 30, 2025
Ownership Breakdown
25
Institutional Holders
▲ 1 vs Q2
$127,540
Total Inst. Value
▲ $19,892 vs Q2
560,964
Shares Outstanding
freeFloat 100.00%
2.56M
13F Shares Held
▼ 99,302 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
SLXNW largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
POLAR ASSET MANAGEMENT PARTNERS INC. biological products, (no diagnostic substances) | 743.5K | 128.29% | 128.29% | $26.17M | Dec 1, 2025 | — held |
LINDEN ADVISORS LP biological products, (no diagnostic substances) | 337.5K | 58.24% | 58.24% | $12.18M | Nov 14, 2025 | — held |
ARISTEIA CAPITAL LLC biological products, (no diagnostic substances) | 236.5K | 40.82% | 40.82% | $8.34M | Nov 14, 2025 | — held |
SUSQUEHANNA INTERNATIONAL GROUP, LLP biological products, (no diagnostic substances) | 220.1K | 37.97% | 37.97% | $7.75M | Nov 14, 2025 | ▲ 69.1K |
CLEAR STREET GROUP INC. biological products, (no diagnostic substances) | 219.6K | 37.89% | 37.89% | $7.73M | Nov 14, 2025 | NEW |
HARTREE PARTNERS, LP biological products, (no diagnostic substances) | 182.4K | 31.47% | 31.47% | $7.29M | Nov 13, 2025 | NEW |
SECURITY BENEFIT LIFE INSURANCE CO /KS/ biological products, (no diagnostic substances) | 150.0K | 25.88% | 25.88% | $5.28M | Nov 12, 2025 | — held |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 116.6K | 20.13% | 20.13% | $4.11M | Nov 14, 2025 | ▲ 3.1K |
KEPOS CAPITAL LP biological products, (no diagnostic substances) | 100.0K | 17.26% | 17.26% | $4.00M | Nov 13, 2025 | — held |
JANE STREET GROUP, LLC biological products, (no diagnostic substances) | 74.9K | 12.93% | 12.93% | $2.64M | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
2
Increased
+72.1K shares3
New Positions
first time holders0
Decreased
−0 shares1
Sold Out
fully exitedNet shares change (top 50)
+72.1K
+72.1K / −0
Net new holders
+4
3 new / 1 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
SLXNW insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Shirvan Mitchell CSO and CDO | Jun 4, 2026 | Award | 6,000 | — | — | 8.8K | Form 4 ↗ |
Horenshtein Hadar Mirit CFO and Secretary | Jun 4, 2026 | Award | 7,500 | — | — | 12.5K | Form 4 ↗ |
Hadar Ilan Chairman and CEO | Jun 4, 2026 | Award | 10,000 | — | — | 16.5K | Form 4 ↗ |
Shirvan Mitchell CSO and CDO | Mar 26, 2026 | Sale | 22,818 | $1.36 | $31.0K | 27.9K | Form 4 ↗ |
Noy Shlomo director | Feb 20, 2026 | Award | 9,091 | — | — | 25.4K | Form 4 ↗ |
Noy Shlomo director | Feb 20, 2026 | Award | 10,685 | $1.65 | $17.6K | 10.7K | Form 4 ↗ |
Alon Ruth director | Feb 20, 2026 | Award | 10,685 | $1.65 | $17.6K | 10.7K | Form 4 ↗ |
Alon Ruth director | Feb 20, 2026 | Award | 9,091 | — | — | 10.2K | Form 4 ↗ |
Shirvan Mitchell CSO and CDO | Feb 20, 2026 | Award | 49,726 | — | — | 50.7K | Form 4 ↗ |
Horenshtein Hadar Mirit CFO and Secretary | Feb 20, 2026 | Award | 49,726 | — | — | 50.1K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Silexion Therapeutics Ltd. (SLXNW) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 0.00%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Silexion Therapeutics Ltd. is POLAR ASSET MANAGEMENT PARTNERS INC., holding approximately 743,475 shares — equal to 128.29% of outstanding shares — as of September 30, 2025.
A total of 25 institutional investors currently hold SLXNW stock, with a combined institutional value of approximately $127,540 as of the most recent 13F filing period.
Frequently asked questions
SLXNW ownershipSilexion Therapeutics Ltd. (SLXNW) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is POLAR ASSET MANAGEMENT PARTNERS INC. with a 128.29% stake. Company insiders hold 0.00%. Data sourced from SEC Form 13F as of September 30, 2025.